Vivek Garipalli
Co-Founder @ CarePoint Health
New York, United States
Vivek Garipalli is a seed investor at CarePoint Health in New York focused on Health Care and Medical. Vivek Garipalli was the Co-Founder, CEO, and Board Member of Clover Health. He attended Emory University.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Vivek Garipalli invests in
Stages Vivek Garipalli invests in
Countries Vivek Garipalli invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $2.5M–$8.9M
- Series A
- $3M–$22M
- Series B
- $35M–$100M
Investment Focus
Industry
- Health Care 15 (56%)
- Medical 5 (19%)
- Artificial Intelligence 4 (15%)
- FinTech 3 (11%)
- mHealth 3 (11%)
Stage
- Seed 13 (48%)
- Series A 7 (26%)
- Series B 2 (7%)
- Pre-Seed 1 (4%)
- Series C 1 (4%)
Country
- United States 18 (67%)
- India 1 (4%)
- Brazil 1 (4%)
- Israel 1 (4%)
- New Zealand 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Emm
|
Emm is developing the next generation of consumer health tools to manage your health on your terms. We want to empower everyone to change the quality of their life by inherently understanding their health though technology and specialist knowledge. | $8.9M / Seed / Nov 19, 2025 | |
World Class Health
|
World Class Health is a Hospitals and Health Care company. | $8M / Seed / Nov 20, 2024 | |
Character Biosciences
|
Biopharmaceutical research and development company that's an affiliate of Clover Health | $18M / Series A / May 17, 2022 | |
Swiftly
|
Swiftly is the AI platform purpose-built for retail, serving retailers, wholesalers, and brands. Swiftly's AI agents unify data, automate workflows, and power the marketing that drives measurable growth — connecting shopper engagement, operations, and personalized experiences into one intelligent platform. Swiftly AI is built on theindustry's largest proprietary retail dataset: live transactions, 9 million products, and the closed-loop campaign outcomes of 33,000 stores. That foundation powers faster decisions, smarter execution, and AI-native experiences across the retail ecosystem. Trusted by leading retailers, wholesalers, and hundreds of iconic brands, Swiftly accelerates growth, reduces operational drag, and sets a new standard for what AI can do in retail. | $100M / Series B / Mar 08, 2022 | |
|
Swiftly
|
Swiftly is the AI platform purpose-built for retail, serving retailers, wholesalers, and brands. Swiftly's AI agents unify data, automate workflows, and power the marketing that drives measurable growth — connecting shopper engagement, operations, and personalized experiences into one intelligent platform. Swiftly AI is built on theindustry's largest proprietary retail dataset: live transactions, 9 million products, and the closed-loop campaign outcomes of 33,000 stores. That foundation powers faster decisions, smarter execution, and AI-native experiences across the retail ecosystem. Trusted by leading retailers, wholesalers, and hundreds of iconic brands, Swiftly accelerates growth, reduces operational drag, and sets a new standard for what AI can do in retail. | $100M / Series B / Mar 08, 2022 | |
Uplift
|
UpLift wants to create a future in which a main mental health practitioner is the new standard by providing everyone with access to affordable care. | $8M / Venture - Series Unknown / Dec 14, 2021 | |
Praxis
|
Praxis is a membership-based platform aiming to build an autonomous city. Cities needed to be built around a source of economic opportunity to attract businesses that would create jobs and entice people to relocate. The platform enables people to live healthier, more purposeful lives. Praxis was founded in 2020 and is headquartered in New York. | $4.2M / Seed / Dec 01, 2021 | |
NeuraLight
|
NeuraLight is a VC-backed venture on a mission to transform the lives of the billions of people impacted by neurological disorders by digitizing evaluation and care. | $5.5M / Seed / Oct 28, 2021 | |
Thyme Care
|
Thyme Care is a healthcare company that provides oncology care management services. The company offers a patient- and provider-integrated oncology solution, partnering with health plans to facilitate whole-person care for their members. Thyme Care seeks to revolutionize cancer care by providing personalized and holistic support to patients. Thecompany envisions a future where every cancer patient can access high-quality, individualized care that meets their unique needs and circumstances. | $22M / Series A / Oct 04, 2021 | |
Yendo
|
Yendo provides a credit card product that utilizes vehicle equity to offer consumers credit limits at various rates. The company's service works like a regular card, is accepted anywhere, and includes features like cash access and credit building options. Yendo offers a simple application process that results in a virtual card before thephysical card arrives. | $8.5M / Seed / Sep 30, 2021 | |
| See all 27 investments → | |||
Co-Investors
About CarePoint Health
CarePoint Health, Inc. operates mainly in Texas, USA providing end-to-end non-institutional healthcare services to clients. Licensed by The Texas Department of Health and accredited by The Joint Commission (JCAHO), CarePoint Health has a committed focus on quality management programs by constantly monitoring, evaluating, and improving agencyoperations.CarePoint Health, Inc. operates out of 3 regional offices in Texas.
CarePoint Health Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Achintya Moulick
Chief Executive Officer
|
|||
|
Vivek Garipalli
Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Vivek Garipalli invest in?
Vivek Garipalli invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Vivek Garipalli's check size?
Vivek Garipalli typically joins rounds of $2.5M–$8.9M at Seed, $3M–$22M at Series A and $35M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vivek Garipalli participates in.
How do I contact Vivek Garipalli?
Public channels for Vivek Garipalli include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Vivek Garipalli last invest?
The most recent investment recorded for Vivek Garipalli closed in Nov 2025. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
